Principal Financial Group Inc. Buys 10,492 Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Principal Financial Group Inc. boosted its stake in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 2.5% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 433,924 shares of the life sciences company’s stock after buying an additional 10,492 shares during the quarter. Principal Financial Group Inc. owned approximately 0.56% of Integra LifeSciences worth $9,542,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Wealth Enhancement Advisory Services LLC purchased a new stake in shares of Integra LifeSciences in the first quarter worth about $251,000. Norges Bank bought a new position in shares of Integra LifeSciences in the fourth quarter worth approximately $8,967,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Integra LifeSciences by 3.9% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company’s stock worth $872,000 after purchasing an additional 1,437 shares during the last quarter. GAMMA Investing LLC increased its position in shares of Integra LifeSciences by 3,595.1% in the first quarter. GAMMA Investing LLC now owns 23,353 shares of the life sciences company’s stock worth $5,140,000 after purchasing an additional 22,721 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership grew its position in Integra LifeSciences by 7.1% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock valued at $312,000 after acquiring an additional 913 shares during the last quarter. Institutional investors own 84.78% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on IART. Wells Fargo & Company reduced their price target on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. Argus raised Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Monday, March 31st. JPMorgan Chase & Co. dropped their price target on Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating for the company in a research note on Tuesday, May 6th. Truist Financial lowered their price objective on Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating for the company in a research report on Friday, April 11th. Finally, JMP Securities lowered their price objective on Integra LifeSciences from $35.00 to $25.00 and set a “market outperform” rating for the company in a research report on Friday, May 9th. Four investment analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $18.63.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART opened at $12.21 on Tuesday. Integra LifeSciences Holdings Corporation has a 1-year low of $11.06 and a 1-year high of $32.66. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.21 and a quick ratio of 0.72. The business has a fifty day moving average price of $12.80 and a 200-day moving average price of $18.65. The company has a market capitalization of $948.84 million, a PE ratio of -32.13, a PEG ratio of 0.70 and a beta of 1.15.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Monday, May 5th. The life sciences company reported $0.41 EPS for the quarter, missing the consensus estimate of $0.43 by ($0.02). Integra LifeSciences had a positive return on equity of 12.12% and a negative net margin of 1.78%. The business had revenue of $382.65 million during the quarter, compared to the consensus estimate of $381.17 million. During the same quarter in the previous year, the business posted $0.55 earnings per share. Integra LifeSciences’s quarterly revenue was up 3.7% compared to the same quarter last year. As a group, equities analysts expect that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current fiscal year.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.